--- title: "Guoyuan Securities (HK) Remains a Buy on InnoCare Pharma Ltd. (9969)" type: "News" locale: "en" url: "https://longbridge.com/en/news/305255802.md" description: "Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81.InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74." datetime: "2026-11-12T05:15:37.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305255802.md) - [en](https://longbridge.com/en/news/305255802.md) - [zh-HK](https://longbridge.com/zh-HK/news/305255802.md) generator: "portal-rs" --- # Guoyuan Securities (HK) Remains a Buy on InnoCare Pharma Ltd. (9969) Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81. InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74. ### Related Stocks - [09969.HK](https://longbridge.com/en/quote/09969.HK.md) - [688428.CN](https://longbridge.com/en/quote/688428.CN.md) - [000728.CN](https://longbridge.com/en/quote/000728.CN.md) ## Related News & Research - [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md) - [SDIC Securities Remains a Buy on InnoCare Pharma Ltd. (9969)](https://longbridge.com/en/news/297030913.md) - [Nio Firefly debuts Haven special edition in Oslo, plans spring 2027 launch in Europe](https://longbridge.com/en/news/306380548.md) - [InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization](https://longbridge.com/en/news/303068907.md) - [InnoCare Pharma (SEHK:9969) Climbed, What Is Driving Attention Today?](https://longbridge.com/en/news/303497906.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**